Advertisement
U.S. markets open in 2 hours 8 minutes
  • S&P Futures

    5,307.00
    -1.25 (-0.02%)
     
  • Dow Futures

    40,143.00
    -1.00 (-0.00%)
     
  • Nasdaq Futures

    18,499.00
    -4.75 (-0.03%)
     
  • Russell 2000 Futures

    2,138.80
    +0.40 (+0.02%)
     
  • Crude Oil

    82.31
    +0.96 (+1.18%)
     
  • Gold

    2,231.70
    +19.00 (+0.86%)
     
  • Silver

    24.75
    +0.00 (+0.01%)
     
  • EUR/USD

    1.0796
    -0.0034 (-0.31%)
     
  • 10-Yr Bond

    4.1960
    0.0000 (0.00%)
     
  • Vix

    12.98
    +0.20 (+1.56%)
     
  • GBP/USD

    1.2623
    -0.0015 (-0.12%)
     
  • USD/JPY

    151.3510
    +0.1050 (+0.07%)
     
  • Bitcoin USD

    70,800.75
    +670.72 (+0.96%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,954.55
    +22.57 (+0.28%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ADMS, WSG and BZUN

NEW YORK, NY / ACCESSWIRE / December 12, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Adamas Pharmaceuticals, Inc. (ADMS)
Class Period: August 8, 2017 to September 30, 2019
Lead Plaintiff Deadline: February 10, 2020

The complaint alleges that throughout the class period Adamas Pharmaceuticals, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) health insurers were excluding Adamas's primary product, GOCOVRI, from their prescription formularies or requiring patients to use "step therapy" - i.e., making patients try immediate-release amantadine prior to covering GOCOVRI; (2) the rapid increase in physicians prescribing GOCOVRI during the Class Period was not due to its efficacy; and (3) as a result of the foregoing, the Company's financial statements about Adamas's business, operations, and prospects were materially false and misleading at all relevant times.

Learn about your recoverable losses in ADMS: http://www.kleinstocklaw.com/pslra-1/adamas-pharmaceuticals-inc-loss-submission-form?id=4864&from=1

Wanda Sports Group Company Limited (WSG)
Class Period: Wanda Sports' securities pursuant and/or traceable to the registration statement and related prospectus issued in connection with Wanda Sports' July 26, 2019 initial public offering.
Lead Plaintiff Deadline: January 17, 2020

Throughout the class period, Wanda Sports Group Company Limited allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the lack of major sporting events for its Digital, Production, Sports Solutions ("DPSS") and Spectator Sports segments for its second quarter of 2019, ending before the initial public offering, would negatively impact revenue for the second quarter of 2019; (2) Wanda Sports had suffered a year-over-year decrease in revenue in its second quarter ended June 30, 2019 and would for its fiscal year 2019, primarily related to lower reimbursement revenues accounted for in its DPSS segment and lack of Spectator Sport segment offsets; and (3) as a result, Defendants' statements about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Learn about your recoverable losses in WSG: http://www.kleinstocklaw.com/pslra-1/wanda-sports-group-company-limited-loss-submission-form?id=4864&from=1

Baozun Inc. (BZUN)
Class Period: Baozun American Depository Receipts between March 6, 2019 and November 20, 2019
Lead Plaintiff Deadline: February 10, 2020

Baozun Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (a) Baozun was heavily reliant upon a single brand partner, Huawei, for the exponential service fee growth it had been reporting historically, which was in turn fueling its historical revenue growth; (b) compared to other brands Baozun had as brand partners, the Huawei work had historically included a lot of additional add-on service fees, increasing the revenue reported from Huawei vis-a-via its other brand partners; (c) Huawei, like other large brands, was actively preparing to bring its online merchandising in-house, meaning Baozun knew that it was losing a significant brand partner; and (d) as a result of the foregoing, the Company was not on track to achieve the financial results and performance Defendants claimed the Company was on track to achieve during the class period.

Learn about your recoverable losses in BZUN: http://www.kleinstocklaw.com/pslra-1/baozun-inc-loss-submission-form?id=4864&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm



View source version on accesswire.com:
https://www.accesswire.com/570122/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-ADMS-WSG-and-BZUN

Advertisement